Kyle Halliwill
Overview
Explore the profile of Kyle Halliwill including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
279
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Li Y, Kandyba E, Halliwill K, Delrosario R, Tran Q, Bayani N, et al.
Cancer Discov
. 2025 Mar;
PMID: 40073432
Historical studies performed nearly a century ago using mouse skin models identified two key steps in cancer evolution: initiation, a likely mutational event, and promotion, driven by inflammation and cell...
2.
Taylor M, Kandyba E, Halliwill K, Delrosario R, Khoroshkin M, Goodarzi H, et al.
Science
. 2024 May;
384(6699):eadi7453.
PMID: 38815020
Stem cells play a critical role in cancer development by contributing to cell heterogeneity, lineage plasticity, and drug resistance. We created gene expression networks from hundreds of mouse tissue samples...
3.
Baumgartner C, Ebrahimi-Nik H, Iracheta-Vellve A, Hamel K, Olander K, Davis T, et al.
Nature
. 2023 Oct;
622(7984):850-862.
PMID: 37794185
Immune checkpoint blockade is effective for some patients with cancer, but most are refractory to current immunotherapies and new approaches are needed to overcome resistance. The protein tyrosine phosphatases PTPN2...
4.
Taylor M, Kandyba E, Halliwill K, Delrosario R, Koroshkin M, Goodarzi H, et al.
bioRxiv
. 2023 May;
PMID: 37215032
Adult mammalian stem cells play critical roles in normal tissue homeostasis, as well as in tumor development, by contributing to cell heterogeneity, plasticity, and development of drug resistance. The relationship...
5.
Turan T, Kongpachith S, Halliwill K, McLaughlin R, Binnewies M, Reddy D, et al.
Cancer Immunol Res
. 2023 Apr;
11(6):732-746.
PMID: 37023414
The development of immune checkpoint-based immunotherapies has been a major advancement in the treatment of cancer, with a subset of patients exhibiting durable clinical responses. A predictive biomarker for immunotherapy...
6.
Park B, Mattox A, Clayburgh D, Patel M, Bell R, Yueh B, et al.
Oral Oncol
. 2022 Oct;
135:106183.
PMID: 36215771
PD-L1 testing guides therapeutic decision-making for head and neck squamous cell carcinoma (HNSCC). We sought to understand whether chemoradiation therapy (CRT) influences the PD-L1 combined positive score (CPS) and other...
7.
Chan S, Belmar N, Ho S, Rogers B, Stickler M, Graham M, et al.
Nat Cancer
. 2022 Mar;
3(3):337-354.
PMID: 35256819
Costimulatory receptors such as glucocorticoid-induced tumor necrosis factor receptor-related protein (GITR) play key roles in regulating the effector functions of T cells. In human clinical trials, however, GITR agonist antibodies...
8.
Turan T, Kongpachith S, Halliwill K, Roelands J, Hendrickx W, Marincola F, et al.
Br J Cancer
. 2020 Dec;
124(7):1340.
PMID: 33277603
No abstract available.
9.
Turan T, Kongpachith S, Halliwill K, Roelands J, Hendrickx W, Marincola F, et al.
Br J Cancer
. 2020 Nov;
124(4):760-769.
PMID: 33139798
Background: The balance between immune-stimulatory and immune-suppressive mechanisms in the tumour microenvironment is associated with tumour rejection and can predict the efficacy of immune checkpoint-inhibition therapies. Methods: We consider the...
10.
Roelands J, Hendrickx W, Zoppoli G, Mall R, Saad M, Halliwill K, et al.
J Immunother Cancer
. 2020 May;
8(1).
PMID: 32376723
Background: An immune active cancer phenotype typified by a T helper 1 (Th-1) immune response has been associated with increased responsiveness to immunotherapy and favorable prognosis in some but not...